Ā | Age | Male/female | WBC (Ī¼L) | CRP (mg/dL) | MDW |
---|---|---|---|---|---|
Total (Nā=ā232) | 70 (13ā96) | 109/123 | 6700 (500ā21,100) | 0.565 (0.01ā31.46) | 19.0 (13.6ā30.2) |
Acute respiratory infection (Nā=ā141) | 69 (15ā92) | 67/74 | 7200 (500ā21,100) | 1.59 (0.01ā31.46) | 19.4 (15.0ā28.2) |
Ā Mild (Nā=ā80) | 54.5 (15ā92) | 33/47 | 6550 (500ā21,100) | 0.37 (0.01ā13.64) | 18.9 (15.0ā27.2) |
Ā Moderate I (Nā=ā52) | 77.5 (15ā90) | 30/22 | 9350 (2100ā17,900) | 3.96 (0.46ā31.46) | 20.0 (16.4ā28.2) |
Ā Moderate II (Nā=ā9) | 79 (35ā91) | 4/5 | 6500 (3700ā13,800) | 9.21 (0.46ā22.55) | 21.2 (16.5ā25.0) |
Nonrespiratory infection (Nā=ā19) | 64 (13ā87) | 7/12 | 8400 (3800ā18,100) | 5.01 (0.03ā23.15) | 23.0 (16.6ā30.2) |
Viral infection (Nā=ā1) (generalized herpes zoster) | 81 | 0/1 | 3100 | 1.84 | 27.7 |
After treatment for COVID-19 (Nā=ā11) [median time from onset to testing: 43Ā days (11ā140Ā days)] | 68 (24ā75) | 7/4 | 5500 (2600ā9000) | 0.09 (0.02ā0.7) | 18.1 (16.6ā21.7) |
Contacted with COVID-19 patients (Nā=ā1) | 21 | 1/0 | 6100 | 0.01 | 16.2 |
Noninfectious disease (Nā=ā59) | 72 (17ā96) | 26/33 | 5400 (3200ā12,800) | 0.11 (0.01ā6.5) | 18.0 (13.6ā21.7) |